Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Biovest Intl Inc Com (NASDAQOTCBB:BVTIQ)

CAPS Rating: No stars

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

8 Outperform
6 Underperform
 

All-Star Players

0 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQOTCBB:BVTIQ Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

DarkToast (30.45)
Submitted April 14, 2010

Biovest is emerging from bankruptcy. They make individualized vaccines for non hodgkins lymphoma. Their products are in use in Europe and have been granted orphan drug status by the FDA.A reorganization plan will be announced any day. Accentia… More

TMFStockSpam (27.30)
Submitted November 19, 2010

BIOVEST INTERNATIONAL INCORPORATED (OTCBB: BVTI) "Up 3.33% in morning trading"Detailed Quote: http://www.otcpicks.com/quotes/BVTI.phpBiovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for… More

NASDAQOTCBB:BVTIQ VS S&P 500 (SPY)

NASDAQOTCBB:BVTIQ Summary

Fools bullish on NASDAQOTCBB:BVTIQ are also bullish on:

Fools bearish on NASDAQOTCBB:BVTIQ are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BVTIQ.

Recs

1
Member Avatar TMFStockSpam (27.30) Submitted: 11/19/2010 5:31:25 PM : Underperform Start Price: $1.32 NASDAQ OTC:BVTIQ Score: +372.86

BIOVEST INTERNATIONAL INCORPORATED (OTCBB: BVTI)
"Up 3.33% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BVTI.php
Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ: ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently completing a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.
BVTI News:
November 15 - New Phase III Data Analysis for BiovaxID®, Personalized Lymphoma Vaccine, to Be Presented at ASH Annual Meeting
Biovest International, Inc. (OTC: BVTI) announced that BiovaxID®, Biovest’s personalized lymphoma vaccine, will be featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Monday, December 6th in Orlando, Florida.
Stephen J. Schuster, M.D., Associate Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, will deliver the BiovaxID presentation titled, “Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration in Follicular Lymphoma Patients.”

Recs

2
Member Avatar DarkToast (30.45) Submitted: 4/13/2010 9:21:17 PM : Outperform Start Price: $1.80 NASDAQ OTC:BVTIQ Score: -373.31

Biovest is emerging from bankruptcy. They make individualized vaccines for non hodgkins lymphoma. Their products are in use in Europe and have been granted orphan drug status by the FDA.

A reorganization plan will be announced any day. Accentia (ABPIQ) owns majority interest in Biovest. Accentia is also emerging from BK any day now. They have some other drugs they are working on like Sinunase, but the winner in BiovaxID, the personlized cancer vaccine.

The stock has experience a ridiculous run up since I first blogged about it in April of 2008 when it was .47 cents, but only after a plunge to .10.

This stock experiences wild volatility. The volume is thin. When they make a presentation to doctors or investors the price can fluctuate quite a bit.

Leaderboard

Find the members with the highest scoring picks in BVTIQ.

Score Leader

stockjock11

stockjock11 (20.04) Score: +378.20

The Score Leader is the player with the highest score across all their picks in BVTIQ.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
stockjock11 20.04 4/7/2010 Underperform 5Y $1.80 -98.94% +279.25% +378.20 0 Comment
TMFStockSpam 27.30 11/18/2010 Underperform NS $1.32 -98.56% +274.30% +372.86 1 Comment
Scottie31 83.86 12/3/2010 Underperform 5Y $1.20 -98.42% +267.46% +365.88 0 Comment
SneakyPete21 < 20 12/6/2010 Underperform 5Y $1.30 -98.54% +267.16% +365.70 0 Comment
liszewski 99.86 12/7/2010 Underperform 5Y $1.19 -98.40% +263.28% +361.68 0 Comment
NachOben < 20 2/16/2011 Underperform 3M $0.72 -97.36% +236.16% +333.52 0 Comment
FishSRQ 25.60 1/11/2011 Outperform 5Y $0.85 -97.76% +253.30% -351.07 0 Comment
MTBB 25.94 12/21/2010 Outperform 3Y $0.95 -97.99% +260.23% -358.22 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. DarkToast 30.45 4/14/2010 Outperform 3Y $1.80 -98.94% +274.37% -373.31 2 Comments
MoTrFinger < 20 5/5/2010 Outperform 5Y $1.67 -98.86% +283.35% -382.22 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BVTIQ.